BioStock: Double thumbs up for Medivir from the FDA

Medivir’s drug candidate MIV-711 has received both Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of the rare childhood disease Legg-Calvé-Perthes disease.
– LCPD is a disease with a high risk of future complications such as osteoarthritis. MIV-711 has the potential to be the first drug to have a positive impact on disease progression, says Jens Lindberg, CEO of Medivir.

Read the full interview with Jens Lindberg at biostock.se:

https://www.biostock.se/en/2024/05/double-thumbs-up-for-medivir-from-the-fda/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/